PMID- 35571117
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220519
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Efficacy and Safety of Qili Qiangxin Capsule on Dilated Cardiomyopathy: A 
      Systematic Review and Meta-Analysis of 35 Randomized Controlled Trials.
PG  - 893602
LID - 10.3389/fphar.2022.893602 [doi]
LID - 893602
AB  - Objective: Qili Qiangxin Capsule (QQC), a Chinese patent medicine, is clinically 
      effective in treating dilated cardiomyopathy (DCM). However, the meta-analysis of 
      QCC combined with conventional western medicine (CWM) on DCM remains unexplored. 
      This study aimed to systematically evaluate the efficacy and safety of QCC in the 
      treatment of DCM. Methods: Searched the studies of the combination of QQC and CWM 
      in the treatment of DCM, from databases like PubMed, Cochrane Library, Web of 
      Science, Wan Fang Databases, Chinese Biomedical Literature Database, China 
      Science and Technology Journal Database, China National Knowledge Infrastructure, 
      prior to 15 January 2022. Two reviewers respectively regulated research 
      selection, data extraction, and risk of bias assessment. Review Manager Software 
      5.4 was used for meta-analysis. Furthermore, GRADE pro3.6.1 software was selected 
      to grade the current evidence in our findings. This meta-analysis has been 
      registered in PROSPERO (CRD42022297906). Results: There were 35 studies 
      pertaining to 3,334 patients included. The meta-analysis showed compared with CWM 
      alone, the combination therapy had significant advantages in improving the 
      clinical efficiency rate (RR = 1.24, 95% CI: 1.19 to 1.29, p < 0.00001), 6 min 
      walking distance (6MWD) (MD = 41.93, 95%CI: 39.82 to 44.04, p < 0.00001), 
      superior in ameliorating the left ventricular ejection fraction (LVEF) (MD = 
      5.73, 95%CI: 4.70 to 6.77, p < 0.00001), left ventricular end-diastolic dimension 
      (LVEDD) (MD = -4.09, 95%CI: -4.91 to -3.27), p < 0.00001), left ventricular 
      end-systolic diameter (LVESD) (MD = -4.73, 95%CI: -5.63 to -3.84), p < 0.00001) 
      and BNP (MD = -101.09, 95%CI: -132.99 to -69.18), p < 0.00001), and also superior 
      in reducing hypersensitive-C-Reactive Protein (hs-CRP) (MD = -3.78, 95%CI: -4.35 
      to -3.21), p < 0.00001), Interleukin- 6 (IL-6) (MD = -25.92, 95%CI: -31.35 to 
      -20.50), p < 0.00001), tumor necrosis factor-alpha (TNF-alpha) (MD = -5.04, 95%CI: -6.13 
      to -3.95), p < 0.00001), high mobility group protein B1 (HMGB1) (MD = -4.34, 
      95%CI: -5.22 to -3.46), p < 0.00001), and adverse reactions (ARs) (RR = 0.70, 
      95%CI: 0.51-0.97), p = 0.03). The GRADE evidence quality rating presented with 
      moderate or low quality of evidence for the available data. Conclusion: Compared 
      with the control group, QQC combined with CWM may be effective in treating DCM. 
      However, the conclusion of this study must be interpreted carefully due to the 
      inferior quality and ambiguity of bias in the included trials. Systematic Review 
      Registration: https://www.crd.york.ac.uk/prospero, identifier [CRD42022297906].
CI  - Copyright (c) 2022 Wei, Li, Wang, Li, Hu, Qiao, Zhou, Yu, Sang, Zhu and Wang.
FAU - Wei, Jingjing
AU  - Wei J
AD  - First Affiliated Hospital of Henan University of CM, Zhengzhou, China.
AD  - Henan University of Chinese Medicine, Zhengzhou, China.
FAU - Li, Bin
AU  - Li B
AD  - First Affiliated Hospital of Henan University of CM, Zhengzhou, China.
FAU - Wang, Xinlu
AU  - Wang X
AD  - First Affiliated Hospital of Henan University of CM, Zhengzhou, China.
FAU - Li, Xingyuan
AU  - Li X
AD  - Henan University of Chinese Medicine, Zhengzhou, China.
FAU - Hu, Yucai
AU  - Hu Y
AD  - Henan University of Chinese Medicine, Zhengzhou, China.
FAU - Qiao, Lijie
AU  - Qiao L
AD  - Henan University of Chinese Medicine, Zhengzhou, China.
FAU - Zhou, Cheng
AU  - Zhou C
AD  - Henan University of Chinese Medicine, Zhengzhou, China.
FAU - Yu, Peng
AU  - Yu P
AD  - Henan University of Chinese Medicine, Zhengzhou, China.
FAU - Sang, Tianqing
AU  - Sang T
AD  - Henan University of Chinese Medicine, Zhengzhou, China.
FAU - Zhu, Mingjun
AU  - Zhu M
AD  - First Affiliated Hospital of Henan University of CM, Zhengzhou, China.
FAU - Wang, Yongxia
AU  - Wang Y
AD  - First Affiliated Hospital of Henan University of CM, Zhengzhou, China.
LA  - eng
PT  - Systematic Review
DEP - 20220428
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9095857
OTO - NOTNLM
OT  - Qili Qiangxin capsule
OT  - dilated cardiomyopathy
OT  - grade
OT  - meta-analysis
OT  - randomized controlled trials
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/17 06:00
MHDA- 2022/05/17 06:01
PMCR- 2022/04/28
CRDT- 2022/05/16 03:54
PHST- 2022/03/10 00:00 [received]
PHST- 2022/04/12 00:00 [accepted]
PHST- 2022/04/12 00:00 [accepted]
PHST- 2022/05/16 03:54 [entrez]
PHST- 2022/05/17 06:00 [pubmed]
PHST- 2022/05/17 06:01 [medline]
PHST- 2022/04/28 00:00 [pmc-release]
AID - 893602 [pii]
AID - 10.3389/fphar.2022.893602 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Apr 28;13:893602. doi: 10.3389/fphar.2022.893602. 
      eCollection 2022.